5 Top Gainers In Healthcare Sector (SOLY, ADVM, BLFS...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Soliton Inc. (SOLY)

Gained 61.85% to close Monday's (July 8) trading at $18.50.

News: The Company is all set to release the cumulative 26-week patient data from its proof of concept clinical trial of a new version of its Rapid Acoustic Pulse (RAP) device for the treatment of moderate to severe cellulite on Monday, July 15, 2019.

The results from the 26-week assessment are being presented at The Aesthetics Show in Las Vegas on July 12, 2019.

The 12-week data from the proof of concept clinical trial were reported in May of this year. According to the trial results, 100% of the patients showed clinical improvement - with the range of improvement in cellulite severity score being 20% to 47% and the average improvement for all patients being nearly a 30% improvement.

Recent event:

The Company received FDA clearance to market its Rapid Acoustic Pulse ("RAP") device for tattoo removal on May 28, 2019.

2. Adverum Biotechnologies Inc. (ADVM)

Gained 22.53% to close Monday's trading at $14.90.

News: The Company announced that it will be presenting the interim 24-week data from its phase I study of intravitreal gene therapy with ADVM-022 for Neovascular (Wet) Age-Related Macular Degeneration, dubbed OPTIC, on September 12, 2019.

3. BioLife Solutions Inc. (BLFS)

Gained 15.91% to close Monday's trading at $18.21.

News: The Company has exercised its option to acquire the remaining 56% of the outstanding shares of privately held SAVSU Technologies in exchange for 1.1 million shares of its (BioLife) common stock.

Commenting on the transaction, Roderick de Greef, BioLife Chief Financial Officer, remarked, "We believe that owning SAVSU will allow BioLife to benefit from the high margin recurring revenue stream associated with the rental model for these products. We look forward to providing more details of this transaction and to revising our financial outlook during our Q2 2019 earnings call, scheduled for August 8, 2019 at 4:30 PM Eastern time."

4. Oasmia Pharmaceutical AB (publ) (OASM)

Oasmia Pharmaceutical develops and sells new generations of drugs in the field of human and veterinary oncology.

Gained 13.43% to close Monday's trading at $2.28.

News: No news

Recent events:

-- On July 5, 2019, an agreement was made between Oasmia and its largest shareholder Arwidsro to solve earlier unclear balances and to support the planned commercialization of Oasmia with more capital.

The agreement will result in Oasmia's liabilities decreasing by SEK 60 million and equity increasing by SEK 95 million. The immediate liquidity effect will be positive by SEK 35 million, according to the Company.

-- On June 28, 2019, Sven Rohmann was appointed as acting CEO of Oasmia Pharmaceutical AB, replacing Mikael Asp.

Mikael Asp assumed position as CTO and remains part of Oasmia's management team, being responsible for all technology and manufacturing activities of the company.

5. Eiger BioPharmaceuticals Inc. (EIGR)

Gained 12.97% to close Monday's trading at $11.41.

News: No news

Near-term Catalyst:

-- Regulatory filings in the U.S. and Europe for Lonafarnib in the indications of Progeria and Progeroid Laminopathies are expected to be made in 2019. -- End of phase II meeting for Avexitide in post-bariatric hypoglycemia is slated for this year. -- End of phase II meeting for peginterferon lambda in patients with hepatitis D virus (HDV) infection scheduled for this year.